Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York. more
Time Frame | RPRX | Sector | S&P500 |
---|---|---|---|
1-Week Return | -1.84% | -3.39% | 0.2% |
1-Month Return | -2.64% | -1.92% | 2.72% |
3-Month Return | -11.05% | -10.54% | 7.31% |
6-Month Return | -5.6% | -4.47% | 10.44% |
1-Year Return | -8.15% | 4.06% | 27.53% |
3-Year Return | -34.82% | 0.94% | 30.88% |
5-Year Return | -43.55% | 36.67% | 89.21% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 1.81B | 2.12B | 2.29B | 2.24B | 2.35B | [{"date":"2019-12-31","value":77.05,"profit":true},{"date":"2020-12-31","value":90.12,"profit":true},{"date":"2021-12-31","value":97.24,"profit":true},{"date":"2022-12-31","value":95.02,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 1.02B | 88.11M | 23.00M | 5.67M | 560.66M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":8.64,"profit":true},{"date":"2021-12-31","value":2.26,"profit":true},{"date":"2022-12-31","value":0.56,"profit":true},{"date":"2023-12-31","value":55,"profit":true}] |
Gross Profit | 794.93M | 2.03B | 2.27B | 2.23B | 1.79B | [{"date":"2019-12-31","value":35.07,"profit":true},{"date":"2020-12-31","value":89.74,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":98.46,"profit":true},{"date":"2023-12-31","value":79.15,"profit":true}] |
Gross Margin | 43.82% | 95.85% | 99.00% | 99.75% | 76.19% | [{"date":"2019-12-31","value":43.93,"profit":true},{"date":"2020-12-31","value":96.09,"profit":true},{"date":"2021-12-31","value":99.25,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":76.38,"profit":true}] |
Operating Expenses | (808.92M) | 527.00M | 858.75M | 1.31B | 862.40M | [{"date":"2019-12-31","value":-61.55,"profit":false},{"date":"2020-12-31","value":40.1,"profit":true},{"date":"2021-12-31","value":65.34,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":65.62,"profit":true}] |
Operating Income | 2.62B | 1.59B | 1.43B | 977.50M | 1.49B | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":60.8,"profit":true},{"date":"2021-12-31","value":54.54,"profit":true},{"date":"2022-12-31","value":37.26,"profit":true},{"date":"2023-12-31","value":56.88,"profit":true}] |
Total Non-Operating Income/Expense | (408.00M) | (50.45M) | (302.12M) | (186.63M) | 93.04M | [{"date":"2019-12-31","value":-438.51,"profit":false},{"date":"2020-12-31","value":-54.22,"profit":false},{"date":"2021-12-31","value":-324.71,"profit":false},{"date":"2022-12-31","value":-200.58,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | 2.46B | 1.70B | 1.24B | 230.06M | 1.70B | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":69.15,"profit":true},{"date":"2021-12-31","value":50.43,"profit":true},{"date":"2022-12-31","value":9.35,"profit":true},{"date":"2023-12-31","value":69.07,"profit":true}] |
Income Taxes | 349.33M | 1.15B | 762.45M | 187.23M | 565.25M | [{"date":"2019-12-31","value":30.46,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":66.47,"profit":true},{"date":"2022-12-31","value":16.32,"profit":true},{"date":"2023-12-31","value":49.28,"profit":true}] |
Income After Taxes | 2.11B | 555.00M | 478.75M | 42.83M | 1.13B | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":26.28,"profit":true},{"date":"2021-12-31","value":22.67,"profit":true},{"date":"2022-12-31","value":2.03,"profit":true},{"date":"2023-12-31","value":53.73,"profit":true}] |
Income From Continuous Operations | 2.46B | 1.69B | 1.24B | 230.06M | 1.70B | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":68.62,"profit":true},{"date":"2021-12-31","value":50.43,"profit":true},{"date":"2022-12-31","value":9.35,"profit":true},{"date":"2023-12-31","value":69.07,"profit":true}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | 2.35B | 495.20M | 478.75M | 42.83M | 1.13B | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":21.09,"profit":true},{"date":"2021-12-31","value":20.39,"profit":true},{"date":"2022-12-31","value":1.82,"profit":true},{"date":"2023-12-31","value":48.32,"profit":true}] |
EPS (Diluted) | - | 5.08 | 2.23 | 3.67 | 4.38 | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":43.9,"profit":true},{"date":"2022-12-31","value":72.24,"profit":true},{"date":"2023-12-31","value":86.22,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
RPRX | |
---|---|
Cash Ratio | 0.86 |
Current Ratio | 1.54 |
Quick Ratio | 2.21 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
RPRX | |
---|---|
ROA (LTM) | 5.69% |
ROE (LTM) | 17.28% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
RPRX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.43 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.38 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
RPRX | |
---|---|
Trailing PE | 9.89 |
Forward PE | 8.41 |
P/S (TTM) | 6.53 |
P/B | 1.62 |
Price/FCF | NM |
EV/R | 7.48 |
EV/Ebitda | 8.82 |
PEG | 5.43 |
Royalty Pharma Plc (RPRX) share price today is $24.843
Yes, Indians can buy shares of Royalty Pharma Plc (RPRX) on Vested. To buy Royalty Pharma Plc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in RPRX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Royalty Pharma Plc (RPRX) via the Vested app. You can start investing in Royalty Pharma Plc (RPRX) with a minimum investment of $1.
You can invest in shares of Royalty Pharma Plc (RPRX) via Vested in three simple steps:
The 52-week high price of Royalty Pharma Plc (RPRX) is $30.92. The 52-week low price of Royalty Pharma Plc (RPRX) is $24.7.
The price-to-earnings (P/E) ratio of Royalty Pharma Plc (RPRX) is 9.8898
The price-to-book (P/B) ratio of Royalty Pharma Plc (RPRX) is 1.62
The dividend yield of Royalty Pharma Plc (RPRX) is 3.34%
The market capitalization of Royalty Pharma Plc (RPRX) is $14.80B
The stock symbol (or ticker) of Royalty Pharma Plc is RPRX